LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardi
LIVN - LivaNova PLC
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$79.25
DETAILS
HIGH:
$90.00
LOW:
$66.00
MEDIAN:
$80.50
CONSENSUS:
$79.25
UPSIDE:
7.34%
Stock News
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Tea.
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be.
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F.
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company's OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova's aura6000™ System for the treatment of mod.
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN
Aberdeen Group plc trimmed its position in shares of LivaNova PLC (NASDAQ: LIVN) by 89.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,850 shares of the company's stock after selling 220,443 shares during the quarter. Aberdeen Group plc's holdings in
SG Americas Securities LLC Buys 11,066 Shares of LivaNova PLC $LIVN
SG Americas Securities LLC raised its stake in shares of LivaNova PLC (NASDAQ: LIVN) by 83.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,257 shares of the company's stock after buying an additional 11,066 shares during the quarter. SG Americas
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN
Allspring Global Investments Holdings LLC lessened its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 8.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,832 shares of the company's stock after selling 19,629 shares during the period. Allspring Global Investments Holdings LLC
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
Exchange Traded Concepts LLC purchased a new position in shares of LivaNova PLC (NASDAQ: LIVN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,768 shares of the company's stock, valued at approximately $970,000. A number of other
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova to Announce First-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen.
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages
LivaNova PLC (NASDAQ: LIVN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index (AHI) between 15 and 65.
Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)
The heavy selling pressure might have exhausted for LivaNova (LIVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
LivaNova (NASDAQ:LIVN) vs. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Head to Head Comparison
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) and LivaNova (NASDAQ: LIVN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends. Analyst Recommendations This is
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy
LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Artisan International Small-Mid Fund Q4 2025 Performance Review
The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.
Price Targets
LivaNova price target raised to $90 from $85 at Mizuho
$90.00
(was $66.26)
Mizuho Securities
LivaNova price target raised to $76 from $73 at Barclays
$76.00
(was $66.26)
Barclays
LivaNova price target raised to $80 from $70 at Stifel
$80.00
(was $70.29)
Stifel Nicolaus
Livanova (LIVN) PT Raised to $81 at Needham
$81.00
(was $70.29)
Mike Matson
·
Needham
Piper Sandler on Livanova (LIVN): 'Favorite SMID Value Name On Our List'
$85.00
(was $67.33)
Adam Maeder
·
Piper Sandler
LivaNova price target raised to $67 from $58 at Barclays
$67.00
(was $64.95)
Barclays
LivaNova price target raised to $66 from $56 at Goldman Sachs
$66.00
(was $64.95)
David Roman
·
Goldman Sachs
LivaNova initiated with an Overweight at KeyBanc
$81.00
(was $62.08)
Brett Fishbin
·
KeyBanc
LivaNova price target raised to $72 from $70 at Mizuho
$72.00
(was $63.08)
Anthony Petrone
·
Mizuho Securities
LivaNova price target raised to $75 from $70 at Baird
$75.00
(was $63.05)
Robert W. Baird
LivaNova downgraded to Neutral from Buy at Goldman Sachs
$55.00
(was $52.38)
Goldman Sachs
LivaNova price target lowered to $56 from $58 at Barclays
$56.00
(was $39.17)
Barclays
LivaNova price target lowered to $70 from $80 at Mizuho
$70.00
(was $51.05)
Anthony Petrone
·
Mizuho Securities
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
$65.00
(was $53.90)
David Roman
·
Goldman Sachs
LivaNova upgraded to Outperform from Neutral at Baird
$66.00
(was $48.79)
David Rescott
·
Robert W. Baird
Livanova (LIVN) PT Raised to $72 at Stifel
$72.00
(was $53.45)
Rick Wise
·
Stifel Nicolaus
Stifel Reiterates Buy Rating on Livanova (LIVN)
$70.00
(was $53.16)
Rick Wise
·
Stifel Nicolaus
Stifel on Livanova (LIVN): 'Positive News as OSPREY OSA Trial Hits Early Stop Criteria'
$65.00
(was $56.63)
Rick Wise
·
Stifel Nicolaus
Barclays Initiates Coverage On LivaNova with Equal-Weight Rating, Announces Price Target of $62
$62.00
(was $56.05)
Barclays
Goldman Sachs Maintains Buy on LivaNova, Lowers Price Target to $63
$63.00
(was $53.95)
Goldman Sachs